Parham D M
Department of Pathology and Laboratory Medicine, St. Jude Children's Research Hospital, Memphis, TN 38105.
Curr Opin Oncol. 1993 Jul;5(4):672-7. doi: 10.1097/00001622-199307000-00010.
Current therapy for childhood sarcomas, particularly rhabdomyosarcomas, is a multidisciplinary effort requiring input from various specialists. Significant progress has been made in lower-stage disease because of advances in chemotherapy, radiotherapy, and surgery, but cure rates remain poor in high-stage lesions, and there is significant morbidity after treatment of lesions with a favorable outcome. Histologic classification is not always predictive of behavior, but recent modifications promise better prognostic significance. Great advances have also been made in our understanding of the biology of these lesions; these advances offer the promise of future therapeutic applicability. Detection of genetic alterations in predisposed individuals is possible but raises several significant nontherapeutic issues.
目前针对儿童肉瘤，尤其是横纹肌肉瘤的治疗是一项多学科协作的工作，需要各类专家的参与。由于化疗、放疗和手术方面的进展，低分期疾病已取得显著进展，但高分期病变的治愈率仍然很低，而且预后良好的病变治疗后仍有明显的发病率。组织学分类并不总是能预测肿瘤行为，但最近的修订有望具有更好的预后意义。我们对这些病变生物学的理解也取得了巨大进展；这些进展为未来的治疗应用带来了希望。在易感个体中检测基因改变是可能的，但也引发了几个重要的非治疗性问题。
